Total Payments
$13,808
2017 Payments
$13,808
Companies
3
Transactions
12
Medicare Patients
664
Medicare Billing
$68,732
Payment Breakdown by Category
Research$12,733 (92.2%)
Consulting$1,075 (7.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12,733 | 9 | 92.2% |
| Consulting Fee | $1,075 | 3 | 7.8% |
Payments by Type
Research
$12,733
8 transactions
General
$1,075
3 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $11,808 | 9 | $0 (2017) |
| Amgen Inc. | $2,000 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2017 | $13,808 | 12 | Novartis Pharmaceuticals Corporation ($11,808) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/29/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | Cash or cash equivalent | $1,755.00 | Research |
| Study: OUTCOMES RESEARCH • Category: CARDIOVASCULAR | ||||||
| 09/03/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | Cash or cash equivalent | $405.00 | Research |
| Study: OUTCOMES RESEARCH • Category: CARDIOVASCULAR | ||||||
| 08/11/2017 | Amgen Inc. | Repatha (Biological) | — | Cash or cash equivalent | $750.00 | Research |
| Study: Commentary on the social value of PCSK9i treatments under varying baseline event rates • Category: Cardiology | ||||||
| 08/01/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | Cash or cash equivalent | $1,147.50 | Research |
| Study: OUTCOMES RESEARCH • Category: CARDIOVASCULAR | ||||||
| 07/14/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | Cash or cash equivalent | $810.00 | Research |
| Study: OUTCOMES RESEARCH • Category: CARDIOVASCULAR | ||||||
| 07/07/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | Cash or cash equivalent | $3,476.25 | Research |
| Study: OUTCOMES RESEARCH • Category: CARDIOVASCULAR | ||||||
| 05/18/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | ENTRESTO (Drug) | — | Cash or cash equivalent | $3,138.75 | Research |
| Study: OUTCOMES RESEARCH • Category: CARDIOVASCULAR | ||||||
| 04/21/2017 | Amgen Inc. | — | — | Cash or cash equivalent | $1,250.00 | Research |
| Study: Commentary on the social value of PCSK9i treatments under varying baseline event rates: journal pass-through expenses | ||||||
| 04/21/2017 | Novartis Pharmaceuticals Corporation | SERELAXIN (Drug) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| 03/17/2017 | Novartis Pharmaceuticals Corporation | SERELAXIN (Drug) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| 01/13/2017 | Novartis Pharmaceuticals Corporation | SERELAXIN (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| 2017 | Xhale, Inc. | — | — | — | $0.00 | Ownership |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| OUTCOMES RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $10,733 | 6 |
| Commentary on the social value of PCSK9i treatments under varying baseline event rates: journal pass-through expenses | Amgen Inc. | $1,250 | 1 |
| Commentary on the social value of PCSK9i treatments under varying baseline event rates | Amgen Inc. | $750.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 217 | 289 | $111,043 | $23,002 |
| 2022 | 4 | 163 | 195 | $66,689 | $12,807 |
| 2021 | 4 | 121 | 172 | $53,728 | $11,152 |
| 2020 | 8 | 163 | 233 | $105,932 | $21,771 |
Total Patients
664
Total Services
889
Medicare Billing
$68,732
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 35 | 81 | $23,490 | $5,426 | 23.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 30 | $22,902 | $4,423 | 19.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 25 | 41 | $17,056 | $4,131 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 33 | $17,913 | $3,686 | 20.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 22 | $12,078 | $2,422 | 20.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $11,270 | $2,056 | 18.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 61 | 68 | $6,334 | $858.79 | 13.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 33 | $24,423 | $4,985 | 20.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 42 | 42 | $22,440 | $4,230 | 18.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 21 | 46 | $13,018 | $2,680 | 20.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 71 | 74 | $6,808 | $912.30 | 13.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 40 | $18,800 | $4,175 | 22.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 39 | $16,575 | $3,397 | 20.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 49 | $14,455 | $3,025 | 20.9% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 39 | 44 | $3,898 | $554.65 | 14.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 31 | 74 | $30,770 | $6,663 | 21.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 13 | 20 | $17,896 | $3,761 | 21.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 30 | 36 | $16,110 | $3,494 | 21.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 18 | 18 | $14,544 | $3,166 | 21.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 31 | $9,021 | $1,934 | 21.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 14 | $8,358 | $1,435 | 17.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 16 | 16 | $7,145 | $1,040 | 14.5% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2020 | 24 | 24 | $2,088 | $279.48 | 13.4% |
About Daniel Blumenthal, MD, MBA
Daniel Blumenthal, MD, MBA is a Cardiovascular Disease healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/10/2011. The National Provider Identifier (NPI) number assigned to this provider is 1437444197.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Daniel Blumenthal, MD, MBA has received a total of $13,808 in payments from pharmaceutical and medical device companies, with $13,808 received in 2017. These payments were reported across 12 transactions from 3 companies. The most common payment nature is "" ($12,733).
As a Medicare-enrolled provider, Blumenthal has provided services to 664 Medicare beneficiaries, totaling 889 services with total Medicare billing of $68,732. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease
- Location Jacksonville, FL
- Active Since 06/10/2011
- Last Updated 09/02/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1437444197
Products in Payments
- ENTRESTO (Drug) $10,733
- SERELAXIN (Drug) $1,075
- Repatha (Biological) $750.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Jacksonville
Dominick Angiolillo, Md, MD
Cardiovascular Disease — Payments: $417,748
Cardiovascular Disease $417,748
Dr. Saumil Oza, M.d, M.D
Cardiovascular Disease — Payments: $336,166
Cardiovascular Disease $336,166
Dr. Samer Garas, Md, MD
Cardiovascular Disease — Payments: $264,433
Cardiovascular Disease $264,433
Dr. Albert Seals, Md, MD
Cardiovascular Disease — Payments: $184,323
Cardiovascular Disease $184,323
Dr. Bharat Gummadi, M.d, M.D
Cardiovascular Disease — Payments: $140,527
Cardiovascular Disease $140,527
Dr. Raguveer Murthy, M.d, M.D
Cardiovascular Disease — Payments: $106,493
Cardiovascular Disease $106,493